Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acotec Scientific HoldingsHKSE:06669 -0.47%76 Return-on-Tangible-Equity is 4.50% as of Dec. 2025, which is 4% below its 10-year median of 4.71. GuruFocus rates HKSE:06669 with a GF Score™ of 76/100 and a GF Value™ of HK$14.83 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Acotec Scientific Holdings ranks worse than 63.41% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Acotec Scientific Holdings's annualized net income for the quarter that ended in Dec. 2025 was HK$67.6 Mil. Acotec Scientific Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$1,502.7 Mil. Therefore, Acotec Scientific Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 4.50%.
The historical rank and industry rank for Acotec Scientific Holdings's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:06669'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -17.04 Med: 4.71 Max: 63.67
Current: -3.89
During the past 7 years, Acotec Scientific Holdings's highest Return-on-Tangible-Equity was 63.67%. The lowest was -17.04%. And the median was 4.71%.
HKSE:06669's Return-on-Tangible-Equity is ranked worse than 63.41% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.82
vs HKSE:06669: -3.89
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Acotec Scientific Holdings Return-on-Tangible-Equity Related Terms
Acotec Scientific Holdings Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06669 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Acotec Scientific Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acotec Scientific Holdings Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acotec Scientific Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Acotec Scientific Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.50% mean?
Acotec Scientific Holdings (HKSE:06669) has a Return-on-Tangible-Equity of 4.50% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Acotec Scientific Holdings and its competitors. This is near median its historical median of 4.71. According to the industry distribution chart, Acotec Scientific Holdings ranks #480 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 63.4%.
Is Acotec Scientific Holdings' Return-on-Tangible-Equity too high?
Acotec Scientific Holdings' current Return-on-Tangible-Equity of 4.50% is near median its 10-year median of 4.71. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.82. Acotec Scientific Holdings' value of 4.50% is 6.6% below this industry median. Based on the distribution chart, Acotec Scientific Holdings ranks #480 out of 757 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Acotec Scientific Holdings has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acotec Scientific Holdings' Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acotec Scientific Holdings ranks #480 out of 757 companies for Return-on-Tangible-Equity. This places Acotec Scientific Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.82. Acotec Scientific Holdings' value of 4.50% is 6.6% below this benchmark. While the company's 10-year median is 4.71 vs. the industry median of 4.82, Acotec Scientific Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.82, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acotec Scientific Holdings's current Return-on-Tangible-Equity of 4.50% is 6.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Acotec Scientific Holdings and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acotec Scientific Holdings's current Return-on-Tangible-Equity is 4.50%, which is near median its own 10-year median of 4.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acotec Scientific Holdings stock overvalued right now?
Based on GuruFocus' analysis, Acotec Scientific Holdings (HKSE:06669) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.83, compared to a current price of HK$6.37 — trading 57.1% below its estimated fair value. The current Return-on-Tangible-Equity is 4.50%, which is near median its 10-year median of 4.71 and 6.6% below the Medical Devices & Instruments industry median of 4.82. Acotec Scientific Holdings' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Acotec Scientific Holdings (HKSE:06669), the current Return-on-Tangible-Equity is 4.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acotec Scientific Holdings (HKSE:06669) Overvalued in 2026?
Based on GuruFocus' analysis, Acotec Scientific Holdings stock appears to be undervalued.
The current stock price of HK$6.37 is trading 57.1% below its estimated GF Value™ of HK$14.83.
GuruFocus considers Acotec Scientific Holdings to be Significantly Undervalued.
Key valuation signals for HKSE:06669:
Return-on-Tangible-Equity: 4.50% (near median its 10-year median of 4.71)
GF Value™: HK$14.83 vs. price of HK$6.37 (57.1% below fair value)
Industry Position: 6.6% below the Medical Devices & Instruments median (#480 of 757)
No single metric tells the full story. See the HKSE:06669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acotec Scientific Holdings Ltd is a medical technology company, focusing on the research and development, and application of technology platforms in the field of vascular interventional treatment. Its product portfolio comprises Semi-compliant PTCA balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), Coronary CTO Antegrade Micro-Catheter (Vericor-14), Coronary High-Pressure Balloon (YIYAN), Coronary CTO Retrograde Micro-Catheter (Vericor-RS), Cardiac Valve Balloon Dilation Catheter (RunFlow), etc., and also has various other products in its development pipeline. Geographically, the company generates a majority of its revenue from Mainland China, and the rest from other regions. The firm generates the majority of its revenue from sales to Domestic distributors.
76GF Score
Get the complete analysis for HKSE:06669
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06669 has been successfully added to your 
